Clinical Trials for Heart Failure

362 heart failure trials indexed, 151 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Heart Failure

Heart failure is a chronic condition where the heart cannot pump blood effectively to meet the body’s needs. This happens because the heart muscle becomes weakened or stiff, affecting its ability to fill with or eject blood. The underlying biology involves damage to the heart tissue, often due to coronary artery disease, high blood pressure, or previous heart attacks. Doctors diagnose heart failure using a combination of physical exams, patient history, and tests such as echocardiograms, which use ultrasound to visualize heart function, and blood tests that measure levels of certain proteins indicating heart stress.

Common symptoms of heart failure include shortness of breath, fatigue, swollen legs, and rapid or irregular heartbeat. These symptoms often worsen over time as the heart’s ability to pump declines. Heart failure typically affects adults over the age of 65, though it can occur at younger ages depending on underlying causes. People with high blood pressure, diabetes, obesity, or a family history of heart disease are at higher risk. Lifestyle factors such as smoking and a sedentary lifestyle also increase the chance of developing heart failure.

Heart failure is a significant medical and social concern worldwide. It affects approximately 6.2 million adults in the United States alone. The condition is a leading cause of hospitalizations among older adults, placing a heavy burden on healthcare systems. Mortality rates remain high, with about 50% of patients dying within five years of diagnosis. The economic burden is also substantial, with estimated annual costs exceeding $30 billion due to hospital care, medications, and lost productivity. These facts highlight the need for ongoing research and improved treatment options.

The Heart Failure Treatment Landscape

The first-line treatment for heart failure often begins with lifestyle changes and medications that help the heart work more efficiently. These include drugs like ACE inhibitors or angiotensin receptor blockers, which relax blood vessels and reduce the heart’s workload. Beta-blockers are also commonly prescribed to slow the heart rate and lower blood pressure. Diuretics help remove excess fluid from the body, easing symptoms such as swelling and shortness of breath. Treatment usually follows a stepwise approach, starting with these foundational therapies and adjusting based on symptom severity and patient response.

When first-line treatments are not enough, second- and third-line options come into play. For example, mineralocorticoid receptor antagonists are added to reduce fluid retention and prevent worsening heart failure. Other drug classes include angiotensin receptor-neprilysin inhibitors, which combine two mechanisms to improve heart function. Devices such as implantable cardioverter defibrillators or cardiac resynchronization therapy may also be recommended for certain patients. The choice of these therapies depends on the type of heart failure and individual patient factors.

Despite these options, current treatments do not work equally well for everyone. Some subgroups, such as patients with preserved ejection fraction, have fewer effective therapies available. Others may experience side effects like low blood pressure or kidney problems that limit medication use. Resistance to certain drugs can also develop over time. Research is actively focused on closing these gaps by exploring new drug targets, improving device technology, and better understanding the biology of different heart failure types. This ongoing work aims to provide more personalized and effective care.

Why Clinical Trials Matter for Heart Failure

Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial can also mean closer medical monitoring and support from a research team. For heart failure specifically, there are currently 362 clinical trials indexed on ClinicalTrials.gov, with 151 actively recruiting participants. These studies cover a wide range of interventions, from novel medications to lifestyle programs and device therapies. By joining a trial, patients contribute to scientific knowledge that may improve care for future generations.

It is important to understand the risks involved in clinical trials. New treatments may not be effective and could cause side effects that are not yet fully known. Some trials include placebo arms, meaning participants might receive a non-active treatment instead of the experimental one. Additional clinic visits and tests are often required, which can add to the time and effort needed to participate. Patients should carefully weigh these factors and discuss them with their healthcare providers before enrolling.

The sponsors of heart failure clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in developing and testing new therapies. ClinicalTrials.gov serves as a centralized registry where patients and caregivers can find detailed information about ongoing studies. This transparency helps people make informed decisions about participation and supports the broader effort to advance heart failure treatment through rigorous research.

What to Look for in a Heart Failure Clinical Trial

Clinical trials are divided into four main phases, each with a different purpose. Phase 1 trials test a new treatment’s safety in a small group of people. Phase 2 trials focus on how well the treatment works and continue to check safety. Phase 3 trials compare the new treatment to standard treatments in larger groups. Phase 4 trials happen after a treatment is approved, to monitor long-term effects and safety. For heart failure trials, many studies do not specify a phase (153 trials). Among those that do, Phase 2 trials are the most common with 28, followed by Phase 3 with 22, and Phase 4 with 19 trials.

Inclusion criteria are the rules that decide who can join a clinical trial. For heart failure trials, age is often a key factor, with many studies including adults from 18 years and older, sometimes focusing on older adults. Researchers may require participants to have a specific type of heart failure, such as reduced or preserved ejection fraction. Prior treatments, like certain medications or devices, might be required or excluded. Biomarkers, such as levels of natriuretic peptides, can be used to select patients with active disease. The stage of heart failure and how long a person has had it are also important to ensure the study results apply to the right group.

Exclusion criteria are conditions or factors that prevent someone from joining a trial. These rules protect participants and help ensure clear results. Common exclusions in heart failure trials include other serious illnesses like severe kidney or liver disease. People with certain heart rhythm problems or recent heart attacks may also be excluded. Drug interactions are considered, so participants cannot take medications that might interfere with the study treatment. Safety thresholds, such as very low blood pressure or poor kidney function, help avoid risks during the trial.

Joining a clinical trial means thinking about practical matters too. Trials can last from a few weeks to several months or years. Visit schedules vary but often include regular check-ups, tests, and sometimes hospital stays. Travel to the study site may be needed, which can be a challenge for some patients. Before joining, it is helpful to ask the research team questions like: What are the possible side effects? How often will I need to visit the clinic? Will the study treatment replace my current medications? What happens if I want to stop participating? These questions help you understand what to expect and make an informed decision.

Primary Sources and Further Reading

Finding reliable information about heart failure and clinical trials can help you make informed decisions. Trusted sources provide details about heart failure symptoms, treatments, and ongoing research. Below are several authoritative websites where you can learn more about heart failure and clinical trials.

Latest Research and Emerging Treatments for Heart Failure (2026)

Current heart failure research includes several Phase 3 trials testing new drugs that may offer additional treatment options. One study is evaluating finerenone, a medication that targets harmful hormone pathways affecting the heart and kidneys. This trial (NCT07188805) focuses on children with heart failure and left ventricular systolic dysfunction. If effective, finerenone could help the heart pump more efficiently and ease symptoms such as fatigue and shortness of breath, improving daily life for young patients.

Another important trial is investigating the combination of baxdrostat and dapagliflozin in adults with heart failure and type 2 diabetes (NCT06677060). Baxdrostat works by blocking a hormone involved in blood pressure regulation, while dapagliflozin helps remove excess glucose and sodium through the kidneys. Early data suggests this combination might reduce heart failure events and cardiovascular death. This could mean fewer hospital visits and better symptom control for patients managing both heart failure and diabetes.

Research is also ongoing for maridebart cafraglutide, a drug being tested in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity (NCT07037459). This medication belongs to a class that affects appetite and metabolism, which might help reduce weight and improve heart function. Additionally, studies on ziltivekimab are exploring whether reducing inflammation can lower heart-related complications in people with heart failure (NCT05636176). These new drugs for heart failure show promise in addressing different aspects of the condition, potentially offering more personalized treatment choices in 2026 and beyond.

Frequently asked questions about Heart Failure trials

How do I find Heart Failure clinical trials?

The authoritative source for Heart Failure clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 362 heart failure studies are currently indexed. You can search by entering "heart failure" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new heart failure trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Heart Failure trials in?

Across the 362 heart failure trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Heart Failure clinical trials are currently recruiting?

As of the latest scan, 151 heart failure trials have a "Recruiting" status on ClinicalTrials.gov, out of 362 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting heart failure trial matches their tracked condition.

Stay informed about heart failure research

Get a weekly briefing with the trials that matter most.

Start monitoring heart failure trials